<DOC>
	<DOCNO>NCT00621816</DOCNO>
	<brief_summary>Nitroprusside use commonly Intensive Care Unit long period time order reduce blood pressure . It know body compensates time blood pressure lowering , nitroprusside stop blood pressure go faster rate high start treatment . This study answer question .</brief_summary>
	<brief_title>Sodium Nitroprusside Blood Pressure Reduction ICU ( SNP2 )</brief_title>
	<detailed_description>This phase 2 , multicenter , randomize , double-blind placebo-controlled , parallel group study determine persistence effect SNP blood pressure assess potential rebound hypertension associate prolonged infusion pediatric subject . The primary endpoint change MAP Blinded Study Drug Administration Phase absence stimulus .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nitroprusside</mesh_term>
	<criteria>1 . Subject le 17 year age . 2 . An indwelling arterial line clinically indicate . 3 . Subject 's parent legal guardian willing able give inform parental permission sign date IRBapproved inform parental permission contain element informed consent , subject provide assent , sign IRBapproved require informed assent , applicable . 4 . Subject anticipated require minimum 20 mm Hg ( 15 mm Hg subject &lt; 2 year old ) reduction MAP least 12 hour use SNP [ i.e. , MAPB1 MAPB2 ≥ 20 mm Hg ( 15 mm Hg subject &lt; 2 year old ) ] Exclusion criterion : 1 . Subject weigh &lt; 3.0 kg . 2 . Subject know allergy SNP . 3 . Subject know mitochondrial cytopathy disorder oxidative phosphorylation respiratory chain enzyme . 4 . Subject contraindication vasodilator therapy control blood pressure surgery intensive care unit . 5 . Subject raise intracranial pressure . 6 . Subject anticipate need antihypertensive drug Sodium Nitroprusside either IV ( e.g . dexmedetomidine , esmolol , etc . ) epidural ( e.g.local anesthetic , clonidine , etc . ) within three terminal halflives ( 3X T½ β ) blind study drug period . However , patient receive stable dos antihypertensive drug ( ) prior initiation study drug may enrol . 7 . Subject serious medical condition , opinion investigator , likely interfere study procedure . 8 . Subject moribund ( death likely occur within 48 hour ) . 9 . Subject positive result urine serum HCG test administer screening . 10 . Subject participate clinical trial investigational drug within 30 day prior enrollment 11 . Subject receive received Sodium Thiosulfate within 6 hour prior start openlabel period . 12 . Subject either , anticipate , ECMO .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>nitroprusside</keyword>
	<keyword>intensive care unit</keyword>
	<keyword>hypertension</keyword>
	<keyword>blood pressure reduction</keyword>
</DOC>